AI-enabled physics-based multiscale models power digital twin simulators for in silico oncology and nanomedicine applications.

The goal of the Radhakrishnan Lab is to Create Digital Twin Models in Biomedical Engineering for Cancer Treatment and Next Generation Therapeutics using Nanomedicine. The lab specializes in several computational algorithms spanning the molecular and cellular scales in conjunction with the theoretical formalisms of statistical mechanics, applied machine learning, and high-performance scientific computing in parallel architectures. The lab has forged successful and funded collaborations with pharmacologists, cell biologists, biophysical chemists, anaesthesiologists, and oncologists, primarily through grants from the US National Science Foundation, the US National Institutes of Health, US Department of Energy and the European Research Council. The Lab is also supported by various foundations and through sponsored research from several companies including Corning, Sanofi, Amgen, Siemens Healthineers etc.

The Radhakrishnan lab is strongly committed to adhering to the Penn tenet of In Principle and Practice.